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The Agency for Healthcare Research & Quality (AHRQ) found that Methicillin-resistant Staphylococcus aureus (MRSA)
is associated with up to 375,000 infections and 23,000 deaths in the United States. It is a major cause of surgical site
infections, with a higher mortality and longer duration of care than Methicillin-sensitive Staphylococcus aureus. A
multifactorial bundled approach is needed to control this epidemic, with single interventions unlikely to have a
significant impact on attenuating MRSA infection rates.
Active surveillance has been studied in a wide range of surgical patients, including surgical intensive care and
non-intensive care units; cardiac, vascular, orthopedic, obstetric, head and neck cancer and gastrostomy patients.
There is sufficient evidence demonstrating a beneficial effect of surveillance and eradication prior to surgery to
recommend its use on an expanded basis.
Studies on MRSA surveillance in surgical patients that were published over the last 10 years were reviewed. In at least
five of these studies, the MRSA colonization status of patients was reported to be a factor in preoperative antibiotic
selection, with the modification of treatment regiments including the switching to vancomycin or teicoplanin in MRSA
positive preoperative patients. Several authors also used decolonization protocols on all preoperative patients but used
surveillance to determine the duration of the decolonization.
Universal decolonization of all patients, regardless of MRSA status has been advocated as an alternative prevention
protocol in which surveillance is not utilized. Concern exists regarding antimicrobial stewardship. The daily and
universal use of intranasal antibiotics and/or antiseptic washes may encourage the promotion of bacterial resistance
and provide a competitive advantage to other more lethal organisms.
Decolonization protocols which indiscriminately neutralize all bacteria may not be the best approach. If a patient's
microbiome is markedly challenged with antimicrobials, rebuilding it with replacement commensal bacteria may
become a future therapy.
Preoperative MRSA surveillance allows the selection of appropriate prophylactic antibiotics, the use of extended
decolonization protocols in positive patients, and provides needed data for epidemiological studies.Review
The impact of MRSA
Despite over a decade of interventions, Methicillin-resistant
Staphylococcus aureus (MRSA) remains a significant and
all too common pathogen encountered in the U.S. Health-
care system. Extrapolating data from selected counties from
nine states, the Centers for Disease Control and Prevention
(CDC) estimated that in the United States MRSA caused* Correspondence: healthwatchusa@gmail.com
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fections, requiring a positive MRSA culture from a nor-
mally sterile site, such as blood cultures associated with
bacteremia. Using billing data from U.S. hospitals from
2011, the Agency for Healthcare Research & Quality
(AHRQ) found that more than 460,000 hospitalizations
had a MRSA diagnosis, with 23,000 deaths associated
with these admissions [2]. MRSA is a leading cause of
healthcare associated infections [1,3], and patients
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ported that the average immediate economic impact
from treating a deep incisional or organ space surgical
site infection is $43,970 in patients 65 years and older
[3], not counting possible long term treatment and dis-
ability. Unlike other adverse events, eliminating the oc-
currence of infections cannot be completely controlled
and regulated by a single facility, as infection control
measures at one facility may well affect and contribute
to the MRSA prevalence in other nearby facilities [4].
Many different types of facilities are at risk, along with
their service communities, making the need to control
healthcare associated infections even more imperative.
Colonization rates of Staphylococcus aureus (S. aureus)
in the United States are approximately 30% [5]. The
rate of MRSA colonization in patients admitted to hos-
pitals tend to range from 1.3% to 7.6% [6-8], with colo-
nized patients displaying a higher risk of developing a
MRSA infection [9-13].
Control of this epidemic is multifactorial, with single in-
terventions unlikely to have a significant impact on at-
tenuating MRSA infection rates. Hand hygiene is of
importance, but institutions that only focus on this inter-
vention are unlikely to be successful in controlling MRSA
infections. Surgeons performing even simple office proce-
dures using sterile gloves alone know the difficulties in
maintaining a sterile field. As observed by Lee et al. [14], a
bundle approach was required and neither active sur-
veillance or hand hygiene alone produced significant
reductions in MRSA infections in surgical wards. Using
a screening and decolonization protocol, Rao et al.
observed that none of the 147 (methicillin-sensitive
Staphylococcus aureus) MSSA and 17 MRSA colonized pa-
tients developed an infection post joint arthroplasty [15].
Active surveillance for MRSA has been studied on a
wide range of surgical patients, including surgical inten-
sive care and non-intensive care units; cardiac, vascular,
orthopedic, obstetric, head and neck cancer and gastros-
tomy patients [14,16-18]. The vast amount of the re-
search has centered on the inpatient setting, of which a
combinational or bundled approach has emerged as a
superior intervention in preventing the spread of MRSA
infections [14,18].
Preventative measures for MRSA infections in surgical
patients
Surgeons encounter two different scenarios where MRSA
preventative measures are needed. The first is for surgery
patients admitted to surgical units or intensive care units
where universal surveillance testing and isolation vs univer-
sal daily decolonization have been advocated. The second is
for patients admitted for same-day surgery where preopera-
tive MRSA screening and decolonization can by performed
on an outpatient basis, eliminating the need for isolation.The prevention of the spread of MRSA in surgical
units is of critical importance. Prolonged contact with
the healthcare setting increases the possibility of patients
contracting MRSA from bacteria brought into the facil-
ity by other patients. Thus, the longer the contact and
the sicker the patient the greater the concern.
One of the factors that may have impeded the adoption
of active surveillance protocols [19] was the highly quoted
study published by Harbarth et al. [20]. This study was re-
ferred to in a U.S. Congressional hearing as one of the rea-
sons why the effects of screening are poorly understood
[21,22] and by The Society for Healthcare Epidemiology of
America/Healthcare Infection Control Practices Advisory
Committee (SHEA/HIPAC) as a reason why recommen-
dations regarding active surveillance testing cannot be
made [23].
The Harbarth et al., study was well-controlled and
produced negative findings in regard to the utilization of
active surveillance methods. However, it had methodo-
logical limitations [19] and appeared to have identifiably
known deficiencies in implementation: 31% of the pa-
tients were identified as MRSA carriers after, not before,
the surgery, and only 43% of patients who were known
to be carriers before surgery received preoperative anti-
biotics effective against MRSA [20]. Of the patients who
developed a MRSA infection and were known carriers
prior to surgery, only 66% received prophylaxis against
MRSA and almost 60% did not receive optimal
decolonization of MRSA prior to surgery [20]. In addition,
the study was contradicted by a well-controlled, large
multi-national, multi-institutional study published by Lee
et al. [14], (whose corresponding author was Harbarth)
which reported surveillance along with hand hygiene and
targeted eradication of MRSA to be successful in prevent-
ing MRSA surgical infections.
There are at least 19 studies over the last decade that
observed a beneficial effect of active surveillance in the
prevention of MRSA infections [14-16]. Seventeen of
these studies were reviewed in a recent AHRQ publica-
tion [16]. We reviewed these 19 studies and found that
in 14, observed benefits of active surveillance reached
statistical significance. However, with the exception of
Lee et al. [14], the studies that demonstrated a statisti-
cally significant effect on MRSA have been criticized for
deficiencies in design, not controlling confounding vari-
ables and/or secular trends [16,19]. In other words, the
majority of the studies were a before and after design
and there is a possibility that an unknown factor may
have been present or introduced as these studies were
conducted. Confounding factors may vary results in
either direction. For example, the implementation of an-
other seemingly unrelated protocol might produce an
unexpected augmentation of the intervention’s positive
results or the increase in the rates of MRSA in the
Kavanagh et al. Antimicrobial Resistance and Infection Control 2014, 3:18 Page 3 of 7
http://www.aricjournal.com/content/3/1/18community might produce an unexpected mitigation of
the observed results. However, dominant impacting factors
causing positive results across so many studies is unlikely.
A review of the literature regarding MRSA active sur-
veillance in surgical patients was published by AHRQ in
2013 and failed to make recommendations, despite mul-
tiple studies observing that active surveillance reduces
MRSA infections [16]. Taken together, the negative study
published by Harbarth et al. [20], and the lack of control
for unknown possible confounding factors in the remaining
studies, appeared to be reasons that prevented AHRQ from
making recommendations.
If the studies with known unadjusted confounding
factors (the factor that biased the results is evident) are
disregarded and the myriad of positive studies with a
possible unknown confounding factor are then consid-
ered, the case for the use of active surveillance would be
strengthened.
This is not to say that as new treatments emerge pro-
tocols should not be changed, but not implementing or
having the best practice protocols in place during a ram-
pant epidemic may be a leading cause for the inability to
control multi-resistant organisms in the United States.
This problem was outlined in a 2008 report from the
Government Accountability Office (GAO), which found
a need for the U.S. Department of Health and Human
Services to prioritize the almost 1200 recommended
prevention practices, of which over 500 are strongly
recommended [24]. Recently, Drees et al. [25] found
highly variable definitions and management protocols
for Multidrug resistant gram-negative bacilli and con-
cluded that this variation might contribute to the emer-
gence of these bacteria.
Different prevention protocols are indicated for pa-
tients admitted the day of surgery. In this setting, em-
phasis can be placed on eradication of the carrier state
before surgery. A common protocol was the use of intra-
nasal mupirocin and a daily bathing with either chlor-
hexidine [14,15,26,27] or triclosan [6,28,29] for 5 days.
Several studies required three consecutive negative
swabs before MRSA eradication was confirmed and the
patient could proceed for elective surgery [6,30]. Many
of these patients would not have to be isolated, but one
could argue that they were effectively isolated from the
treatment facility during outpatient decolonization.
There is ample evidence for the beneficial effect of ac-
tive surveillance and eradication prior to surgery. Why
not then subject all patients to the decolonization/eradi-
cation protocols and not perform surveillance? There
are three concerns with this approach. The first is re-
garding the selection of antibiotics for preoperative
prophylaxis, the second is the promotion of bacterial re-
sistance on the targeted bacteria, and the third is the
effect on the microbiome of both the patient and facility.Selection of antibiotics for preoperative prophylaxis
All studies on surgical patients analyzed by AHRQ and
those published by Lee et al. [14], and Rao et al. [15],
were reviewed. At least five of these studies varied the
type of preoperative antibiotic depending upon MRSA
surveillance results [14,15,27,29,31]. The antibiotic was
either ‘modified’ [14], switched to vancomycin [15,27,31]
or combined with teicoplanin [29]. This is important,
because as observed by Gupta et al. [11], vancomycin is
associated with an increase in surgical site infections in
non-MRSA carriers but not in MRSA carriers. An exten-
sive review of this subject was conducted by Crawford
et al. [32], who observed that “…the suspected weaker
activity against MSSA” has been one of the factors in
preventing the routine use of vancomycin for preopera-
tive prophylaxis.
Even though MRSA has been observed to have a
higher mortality and a longer length of treatment than
MSSA [32], MSSA is an important pathogen and has
been observed to be an important causative organism in
hip and knee arthroplasty [15]. If MSSA is detected pre-
operatively, eradication prior to elective surgery has been
observed to reduce surgical site infections [33].
Several authors also used decolonization protocols on
all preoperative patients, but used surveillance to deter-
mine the duration of the decolonization. For example: In
MRSA carriers, Jog et al. [29], used surveillance to ex-
tend the decolonization period with mupirocin and tri-
closan to five days, (United Kingdom’s National Health
Services recommends five days of decolonization for
newly identified carriers [34]), and to substitute preopera-
tive antibiotics gentamicin and teicoplanin for gentamicin
and flucloxacillin. The authors observed a significant re-
duction in MRSA infections.
However, these protocols also relate to the second
concern, the promotion of bacterial resistance, which
may take years or decades to emerge [35]. Of increased
concern is the eradication protocols that are performed
on all patients every day, regardless of colonization sta-
tus, in an inpatient setting or unit. Many decolonization
protocols use both an intranasal antibiotic and an anti-
septic body wash. This results in a repeated and pro-
longed exposure of both the patient’s and facility’s
microbiome to the antimicrobial agents.
Emergence of resistance in the targeted bacteria
Use of intranasal antibiotics
Concern exists regarding the frequent use of intranasal
antibiotics in decolonization protocols. Jog et al. [29],
and Walsh et al. [31], warn of the possible development
of mupirocin resistance. In some facilities, such as nurs-
ing homes, mupirocin resistance can approach 31% in
MRSA carriers [36]. There are also doubts regarding the
effectiveness of decolonization without the use of topical
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intranasal mupirocin in their decolonization protocols.
However, Derde et al. [37] observed decrease MRSA in-
fection with a protocol that used chlorhexidine bathing
that did not incorporate intranasal mupirocin.
The use of antiseptic washes
The use of antiseptic washes are commonly prescribed
preoperatively. In this sense, it is the beginning of prep-
ping a site before surgery. When washing is used for
decolonization it involves the entire body, as the clas-
sical surgical prep is often confined to the surgical site.
The concept of antimicrobial stewardship is important
in the discussion of this topic. No one advocates not
prepping patients for surgery, and use of an antiseptic
wash preoperatively at home is not likely to affect the
microbiome of a facility miles away. Controversy exists
as to whether body washes are used for one day pre-
operatively, five days pre-operatively or if they should be
used on a daily basis on everyone who is admitted to a
surgical intensive care unit. In addition, there is also
controversy on whether or not to use an antiseptic or
just a detergent [38].
Two recent prominent studies have evaluated the daily
and universal use of chlorhexidine decolonization in pre-
venting infections in ICUs. The first, by Haung et al.
[39], using both chlorhexidine and intranasal mupirocin,
did not achieve a statistically significant reduction for
MRSA bloodstream infections, but did for the reduction
in MRSA isolates and for reduction of bloodstream in-
fections in the “Any pathogen” category. However, in the
“Any Pathogen” category, by far the greatest reduction
observed was for commensal bacteria. The clinical trial
originally was to also measure central line-associated
bloodstream infections (CLABSI) and MRSA urinary
cultures, but CLABSI data was dropped due to inability
to acquire standardized denominators and data on the
revised metric, urinary infections, is still pending [40]. A
second article by Derde et al. [37], found that MRSA ac-
quisition decreased with improved hand hygiene and
unit-wide decolonization of patients with chlorhexidine.
However, MRSA chlorhexidine resistance-associated
genes was observed in 13% to 14% and over the short
period of the study, resistance had a statistically non-
significant increase of 11.2% (14 of 110 verses 16 of 113)
[37]. In addition, there was not a reduction in acquisition
of highly resistant Enterobacteriaceae or vancomycin-
resistant enterococci.
Failure of decolonization therapy in MRSA carriers has
been observed by Lee et al. [41] who found a significant
increase in persistent MRSA carriage in patients with a
combined low-level mupirocin and genotypic chlorhexi-
dine resistance. Although the exact mechanism is not
entirely understood, no matter how strong a topicalantiseptic is, a no kill zone may be present. This includes
areas in both the facility and in hard to reach areas of the
patient. In addition, if there is only a bacterial static effect,
reemergence could then occur once the concentration of
the antiseptic falls.
The use of preoperative antibiotics
Similar concerns regarding the development of resist-
ance exist with the parenteral administration of prophy-
lactic antibiotics. The development of gram positive
resistance to vancomycin along with possible weaker ef-
fectiveness against MSSA have been major reasons not
to routinely use prophylaxis [32].
Effects on the microbiome
We live in harmony with commensal bacteria and are
harmed by pathogenic bacteria. The importance of the
types of bacteria residing on and in the body cannot be
overstated. For example, in surgical patients Gupta et al.
[11], observed that post-operative infection rates may
vary after the use of vancomycin prophylaxis depending
upon the colonization status of the patient.
The effects of antimicrobial agents on the micro-
biome is not only that bacteria may develop antimicro-
bial resistance, but also that a selective advantage may
be produced for other bacteria, sometimes even more
virulent, that then take the place of the eradicated
pathogen. For example, the microbiome of the gut is at-
tenuated and challenged with the administration of an-
tibiotics. Post-antibiotic diarrhea may develop and be a
sign of a C. difficle infection. It has been reported that
C. difficile infections can be reduced by over 70% by
restricting the use of ceftriaxone and ciprofloxacin [42]
and, thus, helping to preserve the microbiome of the
patients.
A building’s microbiome is a highly complex and dy-
namic system [43]. As discussed by Kelley and Gilbert
[43] the climate, materials, and building design could have
unexpected and interesting consequences for the selection
and growth of microbes. When the microbiome of a facil-
ity enriches certain traits, “unnatural selection” occurs and
a few bacterial groups will become dominant. Such selec-
tion has been observed to occur in facilities ranging from
hospitals [43] to cheese factories [44].
Many studies reporting rates of resistance to topical
antimicrobials only evaluate the organism the study tar-
gets for reduction. But, a very real theoretical concern is
that the overuse of antibiotics and antiseptics may well
select for other resistant bacterial strains and change the
pathological flora in the building’s environment. For ex-
ample, bacterial spores are resistant to chlorhexidine
body washes [45] which may give a selective advantage
to C. difficile. In addition, reduced susceptibility to
chlorhexidine has been observed in Carbapenem-
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one author to promote the extremely-drug-resistant epi-
demic strain of Klebsiella pneumonia [46].
Indiscriminately neutralizing a patient’s bacteria may
not be the best approach. If a microbiome is markedly
challenged with antimicrobials, rebuilding it with re-
placement commensal bacteria may become a future
therapy. This technique is already taking hold with the
resurgence of research into probiotics and fecal trans-
plants to prevent C. difficile infections [47].
Currently, surveillance is limited to targeted pathologic
bacteria that have high endemic levels in the community
and/or in patients at higher risk for carrying them. How-
ever, someday it may become important and feasible to
know the entire microbiome of patients. This may even
become an essential part of a routine history and physical,
and the surveying for chronic infections or colonizations
by pathologic bacteria may become of great importance. If
our microbiome becomes out of balance unexpected dis-
eases such as gastric ulcers by Helicobacter pylori, chronic
plaque psoriasis from recurrent streptococcal infections
[48], and rheumatoid arthritis from Porphyromonas gingi-
valis may emerge [49].
Conclusion
The vast majority of studies appear to support that sur-
veillance followed by targeted intervention is effective in
reducing surgical site infections. Strong consideration
should be given to classifying surveillance for MRSA as
a U.S. Preventive Services Task Force (USPSTF) Grade B
recommendation, in that “there is a high certainty that
the net benefit is moderate and there is a moderate cer-
tainty that the net benefit is moderate to substantial”
[50]. Indications for active surveillance testing need to
be changed from using on high-risk populations to per-
forming on all except low-risk populations.
The United Kingdom’s National Health Service’s best
practices include MRSA screening of orthopaedics, car-
diothoracic and neurosurgical patients; emergency ortho-
paedic and trauma admissions; critical care admissions; all
elective surgical patients; previous MRSA carriers; oncol-
ogy/chemotherapy patients; renal patients and patients ad-
mitted from high risks settings such as nursing and care
home and all emergency admissions [34]. And “the logical
conclusion of risk factor assessments and the results of
modelling studies is that the most appropriate approach
to the reduction in MRSA carriage in the population, and
resultant MRSA infections, is the universal screening of
all admissions to hospital (either at pre-admission clinics
for elective admissions or immediately on admission for
emergency admissions)” [34].
In the future, knowing the patient’s microbiome may be-
come part of a standard physical examination However,
for now, respecting the microbiome and determiningcarriers of common pathogens of patients treated at a
facility is a prudent practice. Surgeons should strongly
consider decolonization of patients before a surgical
procedure and active surveillance testing for common
pathogens treated at their institution so the principles
of antibiotic stewardship can be followed and proper
antibiotics given.
Universal decolonization versus surveillance and se-
lective decolonization is an area in need of more re-
search. All surgical patients undergo a surgical scrub
and draping, effectively a localized decolonization, before
a surgical incision is performed. And although universal
decolonization at home will not be expected to affect a
facilities’ micorbiome, exposing hospital rooms to de-
cades of daily cleaning of every patient with topical anti-
microbial agents may lead to the promotion of bacterial
resistance. This is not to say that universal decolonization
is not effective but that its long-term implications have
not been extensively studied and may carry additional
risks.
Two recommendations are emerging for the control of
MRSA. The first is to screen for and treat carriers, the
second is universally treat everyone and run the theoret-
ical risk of worsening bacterial resistance and changing
the microbiome of both the patient and the facility. The
decade long policy followed in some, and hopefully few,
facilities of not doing either of these interventions ap-
pears to no longer be an option.
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